



Seeking Research Relating to the Prevention and Spread of the SARS-CoV-2 virus (COVID-19)

IN-PART is an online collaboration platform that connects academic research with teams at over 6,000 R&D intensive companies worldwide, including >95% of the world's top 100 Pharma and Biotech companies. Our platform users are engaged and positioned to directly collaborate with academia to commercialise new research.

To combat the spread of the SARS-CoV-2 virus (COVID-19), we are inviting academics and research commercialisation professionals to submit collaboration and commercialisation opportunities to our network, **with no associated costs nor requirement of an IN-PART subscription.**

Using the template below we ask any university administrator working within research commercialisation, or academic researcher who has conducted or is conducting research **relating to combating COVID-19 directly (e.g. prophylactic or therapeutic vaccines, anti-viral drugs etc.) or indirectly (e.g. protective equipment, diagnostics etc.),** to provide details of their work to our audience, for the purposes of research translation.

Notes on engagement:

- *Information sent will be compiled into a one-page summary and distributed to relevant industry teams via our online platform*
- *Submitting content does not require a subscription to our platform (there will be no costs from IN-PART at any stage)*
- *Full support of our team to draft relevant summaries of content where required*
- *Any information sent to us should be **non-confidential***
- *If you are aware of relevant academics or research taking place to combat the spread of COVID-19, please share this document with them*

Who should submit?

Our audience is interested in collaborating and commercialising research submitted by **academic researchers** or **technology transfer or research commercialisation professional.**

How to submit your opportunity to IN-PART:

- Once you have filled out the template below, please submit this document via email to discover@in-part.co.uk
- Our team will confirm receipt once received

What happens if a company is interested in my submitted research or technology?

Our team will connect you directly with the team of interest in order to begin a conversation about translating the work via routes of commercialisation or collaboration.

Have questions?

Do not hesitate to contact who will be able to help with any questions regarding your research or technology submission: discover@in-part.co.uk

To learn more about IN-PART please see our website for details: www.in-part.com



Project/Research/Technology Title

Title should be no longer than 20 words.

Contact Information (Principal Investigator/Technology Transfer Office)

Name:

Title:

Email:

Phone:

Institution, Department, and Address:

Abstract

Please provide a summary of the research or technology, noting how it relates to combating COVID-19 and: the overall goal; hypothesis; specific aims; clinical rationale; and novelty of approach.

Abstract should be no longer than 250 words.



Research or Technology Description

1. What is the primary therapeutic or prevention area addressed?

2. What is the development stage of the research or technology? *Please use definitions related to the technology sector, e.g. for therapeutics: Discovery, target identification, target validation, hit generation, compound screening, lead generation, in vitro, in vivo, or preclinical validation.*

3. How does the technology or research relate to combating COVID-19 directly or indirectly?

Scientific Background and Rationale

4. Please summarise the hypothesis, background science and rationale, work completed to date, and current stage.



5. Please provide key evidence/data to support the hypothesis.

Research Plan and Milestones

6. Please provide a brief description of the research plan to be carried out to reach your goals.

IP and Legal Considerations

7. Have you previously disclosed this technology to your technology transfer office?

7a If yes, who is your Case Manager? Please include their email address.



8. To the best of your knowledge, what is the prior art in this space? This could include publications, patent applications, and issued patents.

Research Team

9. Please provide a brief biographical sketch of the principal investigator and a list of his or her key publications. An NIH format biosketch or ORCID ID is acceptable.